Maternal Screening, Sequential, Specimen #1
0081293
Ordering Recommendation
Screening test for DS, T18, and ONTD. Risks determined using a combination of 1st and 2nd trimester serum markers, with a 1st trimester NT measurement. Risks provided after both 1st and 2nd trimester specimens are received.
Mnemonic
MS SEQ-1
Methodology
Quantitative Chemiluminescent Immunoassay
Performed
Sun-Sat
Reported
2-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
This test requires a nuchal translucency (NT) measurement that has been performed by a certified ultrasonographer.  The ultrasonographer MUST be certified to perform NT measurements by one of the following agencies: Fetal Medicine Foundation (FMF) or Nuchal Translucency Quality Review (NTQR).  To avoid possible test delays for an ultrasonographer that is new to our database, please contact the genetic counselor at 800-242-2787 extension 2141 prior to sending specimen.

If an NT is unobtainable, order Maternal Serum Screening, Integrated (ARUP test codes 0081062 and 0081064), which can be interpreted without an NT value.

Specimen must be drawn between 11 weeks, 0 days and 13 weeks, 6 days gestation (Crown-Rump length (CRL) must be 4.2-8.5 cm).  
Collect
Serum separator tube or plain red.  
Specimen Preparation
Separate serum from cells ASAP or within 2 hours of collection. Transfer 3 mL serum to an ARUP Standard Transport Tube. (Min: 1 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
A crown rump length greater than 8.5 cm. Plasma. Specimens exposed to repeated freeze/thaw cycles. Hemolyzed specimens.  
Remarks
The sequential maternal screen also requires the following information: a crown-rump length measurement (cm), ultrasonographer's name and certification number, date of ultrasound, patient's date of birth, current weight, due date, number of fetuses present, patient's race, if the patient requires insulin, if there is a known family history of neural tube defects, if the patient has had a previous pregnancy with a chromosome abnormality, if the patient is taking valproic acid or carbamazepine (Tegretol®), physician's name and phone number, and for in vitro fertilization pregnancies, the age of the egg donor.  
Stability
After separation from cells: Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 2 months  
Reference Interval
By report  
Interpretive Data
Refer to report  
Note
 
CPT Code(s)
(84702;84163) or 81508*

*The 2014 AMA CPT manual contains the component CPT Codes and the new MAAA codes.  Please direct any questions regarding CPT coding to the payer being billed.
Components
Component Test Code*Component Chart NameLOINC
0080241Estimated Due Date11778-8
0080917Maternal Weight29463-7
0080920Maternal Screen Interpretation49586-1
0080926Maternal Race21484-1
0080927Number of Fetuses11878-6
0080932Maternal Age At Delivery21612-7
0080935Patient's hCG19080-1
0080937MoM For hCG20465-1
0080938Gestational Age (Exact)18185-9
0081065Nuchal Translucency (NT)12146-7
0081066Crown Rump Length11957-8
0081067Patient's PAPP-A32046-5
0081068MoM for PAPP-A32123-2
0081069Sonographer Certification #49089-6
0081070Sonographer Name49088-8
0081071Ultrasound Date34970-4
0081074MoM for NT49035-9
0081158Family History of Aneuploidy32435-0
0081331Best date to draw sample #2 by61100-4
2002856EER Maternal Screening, Seq, Spec 111526-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • first trimester screen
  • Maternal Serum Sequential Screen
  • Sequential Screening
  • Serum Stepwise Sequential Screen
  • Stepwise Maternal Screen
  • Stepwise Sequential